Nasdaq | The Truth About Skin Care

{ Tag Archives } Nasdaq

PhotoMedex Announces Clinical Trial Using The XTRAC Velocity(R) Laser In The Treatment Of Severe Generalized Psoriasis

Main Category: Eczema / Psoriasis
Also Included In: Dermatology; Clinical Trials / Drug Trials
Article Date: 09 Jun 2010 – 3:00 PDT

email to a friend printer friendly view / write opinions
<!– rate article

PhotoMedex, Inc. (Nasdaq: PHMD) announced that John Koo, MD will be the principal investigator in a clinical study assessing [...]

Also tagged California San Francisco, Clobex Spray, Dennis Mcgrath, Department Of Dermatology, Friendly View, Groundbreaking Study, Health Insur, Koo, Phmd, Photomedex Inc, Psoriasis, Psoriasis Patients, Rate Article, San Francisco Medical Center, Topical Agent, Treatment Protocol, Treatment Regimen, University Of California San Francisco, University Of California San Francisco Medical Center

2010 06 09 Skin Care News Comments Off

NexMed To Discuss P2/3 Protocol For NexACT(R)-Based Alprostadil Treatment For Raynaud’s Syndrome With The FDA

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has granted the Company an Investigational New Drug application number for its NexACT-based alprostadil treatment for Raynaud’s syndrome, ahead of a pre-IND meeting in mid-July 2010 to discuss [...]

Also tagged Ahead, Amp, Application Number, Cro, Drug Administration, Drug Application, Fda, Nexmed Inc, Phase 2, Pipeline, Protocol, Raynaud S Syndrome, Today Announced That

2010 05 19 Skin Care News Comments Off

Molecular Insight Pharmaceuticals Advances Solazed(TM) For Malignant Melanoma Into Phase 1 Clinical Trial

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced the initiation of a Phase 1 clinical trial of Solazed™ (Ioflubenzamide I-131), the Company’s targeted radiotherapeutic drug candidate for treatment of malignant metastatic melanoma…

Also tagged Clinical Trial, Drug Candidate, Initiation, Insight, Malignant Melanoma, Melanoma, Metastatic Melanoma, Mipi, Pharmaceuticals Inc, Phase 1

2010 03 23 Skin Care News Comments Off

New Data Presented At American Burn Association’s Annual Meeting Support Safety Profile Of RECOTHROM® Thrombin, Topical In Pediatric Patients

ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced the presentation of safety and immunogenicity data among pediatric burn patients at the 42nd Annual Meeting of the American Burn Association in Boston, MA. The study marks the first dedicated look at the safety and immunogenicity of any stand-alone thrombin in pediatric surgical patients…

Also tagged American Burn Association, Annual Meeting, Boston Ma, Immunogenicity, Pediatric Patients, Presentation, Safety Profile, Support Safety, Surgical Patients, Thrombin, Zgen, Zymogenetics Inc

2010 03 11 Skin Care News Comments Off

RTI Biologics Donates Matrix HD™ To Treat Young Child With Rare Genetic Skin Condition

RTI Biologics Inc. (RTI) (Nasdaq:RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated a sterilized dermis allograft, Matrix HD™, to treat an eight-year old patient with a rare skin disease called recessive dystrophic epidermolysis bullosa (EB)…

Also tagged Biologics Inc, Dermis, Epidermolysis Bullosa, Hd, Hernia, Implants, Matrix, Rare Disease, Rare Skin Disease, Rti, Rtix, Skin Condition

2010 01 30 Skin Care News Comments Off

Hi-Tech Pharmacal’s ECR Subsidiary To Launch A New Dermatitis Treatment

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals Co., Inc…

Also tagged Dermatitis, Dermatitis Treatment, Dermatological Product, Ecr, Fda, Hi Tech Pharmacal, Hi Tech Pharmacal Co, Hi Tech Pharmacal Co Inc, Hitk, Launch, Marketing, Pharmaceuticals, Subsidiary

2010 01 11 Skin Care News Comments Off

Positive Phase IIb Topline Clinical Data For Celgene Oral Compound Apremilast (CC-10004) Reported For Patients With Moderate-to-Severe Psoriasis

Celgene Corporation (NASDAQ:CELG) announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo…

Also tagged Celg, Double Blind Placebo, Oral Compound, Phase Iib, Plaque Type, Psor, Psoriasis

2009 12 16 Skin Care News Comments Off

Anika Therapeutics Receives European CE Mark Approval For "ELEVESS Light"

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (”HA”) technology, announced that it has received European CE Mark approval for “ELEVESS™ Light,” the Company’s latest aesthetic product used for the treatment of fine lines and facial wrinkles.

Also tagged Aesthetic Product, Anika Therapeutics Inc, Ce Mark, Facial Wrinkles, Hyaluronic Acid

2009 11 21 Skin Care News Comments Off

Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus [...]

Also tagged Adult Patients, Astellas Pharma Us, Astellas Pharma Us Inc, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Gram Positive Bacteria, Launch, Mrsa, September 11, Skin And Skin, Skin Structure Infections, Staphylococcus Aureus, Strains, Telavancin, Theravance Inc, Thrx, United States

2009 11 06 Skin Care News Comments Off

PhotoMedex Offers Free Seminar For Psoriasis Patients: "A Win For Your Skin In The Daily Fight Against Psoriasis"

PhotoMedex, Inc. (Nasdaq: PHMD) a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

Also tagged Free Seminar, Hosting Free, Indianapolis, Laser Products, Medical Laser, Photomedex Inc, Psoriasis, Psoriasis Patients, Skincare

2009 10 29 Skin Care News Comments Off

The Truth About Skin Care

{ Tag Archives } Nasdaq

PhotoMedex Announces Clinical Trial Using The XTRAC Velocity(R) Laser In The Treatment Of Severe Generalized Psoriasis

NexMed To Discuss P2/3 Protocol For NexACT(R)-Based Alprostadil Treatment For Raynaud’s Syndrome With The FDA

Molecular Insight Pharmaceuticals Advances Solazed(TM) For Malignant Melanoma Into Phase 1 Clinical Trial

New Data Presented At American Burn Association’s Annual Meeting Support Safety Profile Of RECOTHROM® Thrombin, Topical In Pediatric Patients

RTI Biologics Donates Matrix HD™ To Treat Young Child With Rare Genetic Skin Condition

Hi-Tech Pharmacal’s ECR Subsidiary To Launch A New Dermatitis Treatment

Positive Phase IIb Topline Clinical Data For Celgene Oral Compound Apremilast (CC-10004) Reported For Patients With Moderate-to-Severe Psoriasis

Anika Therapeutics Receives European CE Mark Approval For "ELEVESS Light"

Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States

PhotoMedex Offers Free Seminar For Psoriasis Patients: "A Win For Your Skin In The Daily Fight Against Psoriasis"

Home

Recommendations

Free Ebook

Latest News

Site Features

Get a free ebook valued at $8.95 when you sign up for our free Skincare Tips newsletter. The book The Truth About Skincare: How To Have Younger Looking Skin sells every day for $8.95 at Bargain Books Web. It's yours at no cost by immediate download when you sign up right now. You can unsubscribe any time, and the book is yours to keep.
Name:
Email: